18.11.2013

Read this issue and previous issues online.

Follow us on:
Follow us on Twitter  Follow us on Facebook  Follow us on Flickr Follow us on YouTube   Follow us on LinkedIn

Announcements / Press Releases

Key learnings for malaria programme managers from AMFm phase 1 [RBM] — (English)
The Roll Back Malaria Partnership has launched a communications package summarizing "Key learnings for malaria programme managers from AMFm phase 1". French and English copies are now available at RBM Subregional Networks...

New malaria vaccines roadmap targets next generation products by 2030 [WHO note for media] — (English)
Partners agree approach for developing vaccines capable of reducing malaria cases by 75% and to enable malaria elimination...

Falsified batches of Coartem recently circulating in Cameroon [WHO Information Exchange System: Drug Alert No. 130] — (English)
Suspect medical products :
Batch Number: NOF 2153
Manufacturing Date 01.2013
Expiry Date: 11. 2015
Batch Number F2929
Manufacturing Date: 01.2012
Expiry Date: 01.2016...


Global Fund Takes Action to Prevent Wrongful Conduct [The Global Fund news release] — (English)
The Global Fund to Fight AIDS, Tuberculosis and Malaria announced today that as part of its broad program to prevent abuse of any kind, it suspended contracts with two international suppliers of mosquito nets after uncovering evidence that they committed serious financial wrongdoing in Cambodia...

Report details policy actions for battling malaria drug resistance [CIDRAP] — (English)
Progress in easing the still-formidable malaria burden is threatened by drug resistance, though there is a narrow window of opportunity to reduce the threat with political leadership, key partnerships among countries and sectors of society, and more financial resources, according to a new report from a global policy group based in Washington, DC...

Drug-Resistant Malaria [CSIS] — (English)
Drug-resistant malaria—or artemisinin resistance—is a major problem, one that has arisen in the Greater Mekong Sub-Region, but could easily emerge in Africa and elsewhere. It stands as a dire threat to the phenomenal progress that has been achieved over the last few years in controlling an ancient and devastating parasitic disease—progress so remarkable that the disease now stands on the brink of elimination...

Fighting Malaria in Africa (Video) [Novartis] — (English)
Rebecca Stevens Alder is proud to be working with Novartis and its partners Roll Back Malaria; Malaria No More; The Global Fund to fight HIV, TB and Malaria; The US President's Malaria Initiative; The World Health Organization; UNICEF; The World Bank; and UNDP. Thanks in part to their efforts, during the past decade, deaths from malaria have fallen 33 percent in Africa, particularly among infants and children...

Novartis honored by Malaria No More corporate citizenship award in recognition of long-standing commitment to eliminating the disease [Novartis Press Release] — (English)
In recognition of Novartis' significant on-going contributions to malaria control and elimination, the company has been honored with the Global Corporate Citizenship Award at the Malaria No More International Honors annual benefit...

Roll Back Malaria Partnership – Development of a Second Generation GMAP [RBM] — (English)
RBM Partnership is seeking proposals from suitably qualified organisations and consortiums to under work in developing the next generation of the Global Malaria Action Plan (GMAP). Proposals must be received no later than Monday 25 November 2013, 12:00 hours, Geneva time to be considered...

RBM Partnership: Secretariat Focal Point for GMAP II [RBM] — (English)
Grade: P 4 level equivalent
Contract type: Consultancy
Application Deadline: 22 November...


RBM Partnership: Development Economist [RBM] — (English)
Contract type: Consultancy
Application Deadline: 22 November...


Consultancy: RBM Advocacy Resource Mobilization for Malaria (ARMM) Toolkit [RBM] — (English)
Application Deadline: 25 November 2013......

University of Oxford - Department of Zoology: Senior Postdoctoral Modeller [University of Oxford] — (English)
Application Deadline: 29 November 2013...

18.11.2013

{title} [{articlesource}] — ({language})
{description}...

17.11.2013

{title} [{articlesource}] — ({language})
{description}...

16.11.2013

{title} [{articlesource}] — ({language})
{description}...

15.11.2013

{title} [{articlesource}] — ({language})
{description}...

14.11.2013

{title} [{articlesource}] — ({language})
{description}...

13.11.2013

{title} [{articlesource}] — ({language})
{description}...

12.11.2013

{title} [{articlesource}] — ({language})
{description}...

Articles requiring subscription or registration

Antimalarial drug discovery — approaches and progress towards new medicines [Nature Reviews Microbiology 11, 849–862 (2013) doi:10.1038/nrmicro3138] — (English)
In this Review, we discuss the cell-, chemistry- and target-based approaches used to discover new drug candidates that are currently in clinical trials or undergoing preclinical testing...

Analyses of Interactions Between Heparin and the Apical Surface Proteins of Plasmodium falciparum [Scientific Reports 3, Article number: 3178 doi:10.1038/srep03178] — (English)
Heparin, a sulfated glycoconjugate, reportedly inhibits the blood-stage growth of the malaria parasite Plasmodium falciparum. Elucidation of the inhibitory mechanism is valuable for developing novel invasion-blocking treatments based on heparin...

Is the 'Other' Malaria Getting More Dangerous? [Science] — (English)
Two new genetic studies of a parasite that causes malaria suggest that it may be evolving new ways to invade human blood cells. The development could make certain strains of the parasite more dangerous for populations who have some natural immunity. Now roughly 95% of people in sub-Saharan Africa—where the malaria burden is the highest—are thought to be resistant to the parasite in question, Plasmodium vivax. If the parasite were to overcome their genetic defense against the disease, it would potentially threaten hundreds of millions more people than it does today...

Treatment for Dormant Malaria Shows Promise [Science] — (English)
The first new drug in half a century to target malaria parasites in one of their best hideouts is showing encouraging results. The researchers developing the drug, called tafenoquine, said today that data from a recently completed phase II trial were promising enough that they will soon start a phase III trial—the last step before asking drug regulators for approval...

Piecing Together the Puzzle of Severe Malaria [Sci Transl Med 13 November 2013: Vol. 5, Issue 211, p. 211ps18] — (English)
Severe malaria manifests as several overlapping syndromes with high mortality. Interaction of parasites with endothelial protein C receptors and high parasite biomass have recently been identified as key determinants of severe disease. However, gaps in our understanding of severe malaria might hinder translation of these findings into new therapies...

TREM2 governs Kupffer cell activation and explains belr1 genetic resistance to malaria liver stage infection [PNAS doi: 10.1073/pnas.1306873110] — (English)
Here we used forward genetics to search for mechanisms underlying natural host resistance to infection and identified triggering receptor expressed on myeloid cells 2 (TREM2) and MHC class II molecules as determinants of Plasmodium berghei liver stage infection in mice. Locus belr1 confers resistance to malaria liver stage infection...

Risk factors for anemia in children under 6 years of age in Ethiopia: analysis of the data from the cross-sectional Malaria Indicator Survey, 2007 [Trans R Soc Trop Med Hyg (2013) 107 (12): 769-776. doi: 10.1093/trstmh/trt096] — (English)
he objective of the analyses presented here were to use the survey's data to identify factors associated with anemia presence in children under 6 years of age (U6); specifically, investigate the association between malaria and anemia; and discuss using anemia as a malaria proxy biomarker in the Ethiopian hypo-endemic transmission setting...

Hospitalizations and Costs Incurred at the Facility Level after Scale-up of Malaria Control: Pre-Post Comparisons from Two Hospitals in Zambia [Am J Trop Med Hyg 2013 13-0019] — (English)
The findings demonstrate that facility-level resources are freed up as malaria is controlled, potentially making these resources available for other diseases and conditions...

Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum [IAI.00866-13] — (English)
In this study, we demonstrate that there is not universal cleavage of MSPs during invasion. Instead, there is sequential and coordinated cleavage and shedding of proteins, indicating a diversity of roles for surface proteins during and after invasion...

A high-content phenotypic screen reveals the disruptive potency of quinacrine and 3’ ,4’ -dichlorobenzamil on the digestive vacuole of Plasmodium falciparum [AAC.01441-13] — (English)
We therefore present as proof-of-concept a phenotypic screen with the potential to provide mechanistic insights to the activity of antimalarial drugs...

Clinical malaria diagnosis in pregnancy in relation to early perinatal mother-to-child transmission of HIV: a prospective cohort study [HIV Medicine] — (English)
We prospectively investigated fever symptoms and maternal diagnosis of malaria in pregnancy (MIP) in relation to child HIV infection among 2368 pregnant HIV-positive women and their infants, followed up from pregnancy until 6 weeks post-delivery in Tanzania...